U.S. Markets closed

Mylan N.V. (MYL)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
30.44-0.28 (-0.91%)
At close: 4:00PM EDT

30.44 0.00 (0.00%)
After hours: 6:20PM EDT

People also watch
TEVAPRGOAGNBIIBENDP
  • s
    scott
    scott
    why is this stock so stupid?
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • V
    Vincent
    Vincent
    This stock is in the toilet along with it's CEO.
  • s
    scott
    scott
    Is they paint dry yet?
  • t
    typea1949
    typea1949
    Ouch
    I've been waiting for the selling to end before getting back into Mylan and Teva

    Longer term, both should be fine as generic pricing will eventually firm up
    Good luck
  • a
    all ready know
    all ready know
    Trade Tip...News is leaking for positive Phase 3 data to be released by Monday. Stock price is beginning to rise on the leak. Cancer/Leukemia drug will spike big time upon press release.

    VSTM
    $3.16
    +0.01 (+0.31%) Duvelisib - DUO
    Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
    Phase 3

    08/31/2017
    Phase 3 data due late summer 2017.
  • Z
    Zeke
    Zeke
    Zacks said today, strong sell. Said because the stock has dropped and earnings have been revised down by others. Said nothing else about the company. Also didn't mention his buy recommendation before the eps report, his prediction of an earnings beat, and his touting his system that showed it would thus gain 28%, on average, over the next 12 months. Well, nobody is perfect. But it doesn't seem like he's adding any value to society. Do these money-shuffler companies make money like this, rather than getting a real job?
  • J
    Jack
    Jack
    LOL! Looking for 33+ today. Might be tough but the short covering should get it there! LOL!
  • G
    Greg
    Greg
    Trade Tip Top... News by Nov eps will be hanging onto 20s. Most hated Pharm next Merk
  • B
    B
    B
    glad I bailed out. Going much lower until the board and mgmt. gone.
  • s
    scott
    scott
    another teva
  • B
    B
    B
    Gave up $80 dollars to TEVA two years ago for $30 today. Simply amazing performance.
  • B
    B
    B
    This management and board makes the "Bad News Bears" wall of Shame.
  • P
    Peter
    Peter
    From Cowan analyst, Gary Cacciattori's note (in a Barron's story yesterday) ... " We have updated our model following the Q2 results, which again were underwhelming. As a result of the H1 performance, management decreased FY17 guidance meaningfully to reflect current operations. We continue to have little faith in the company's ability to get complex products approved or make favorable operational and business development decisions. We would seek better alternatives."
  • J
    Jack
    Jack
    LOL! Like I said the numbers were way better than I expected! Short covering should take this into the green by end of the day! LOL!
  • B
    BTTlll
    BTTlll
    I know a lot of people who lost all their money following awe-some*stocks
  • s
    scott
    scott
    Market shedding points and it's only MYL that is staying green out of ALL my bio stocks....something isn't right. Anyone seeing some flying pig?
  • t
    trader
    trader
    I think it could open at 35 way oversold.
  • P
    Phil X
    Phil X
    MYL already sold off sharply from 39 to 32 in anticipation of weakness in today's report. it should bounce from here unless market chooses to trade irrationally
  • G
    Girg
    Girg
    Blowing Up but they got $100,000,000 to give away